KALVISTA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.78 USD | +2.76% |
|
-6.83% | -12.00% |
Valuation
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 396.7 | 194.7 | 607 | 312.4 | 291.5 | 454.8 | - | - |
| Enterprise Value (EV) 1 | 364.7 | 127 | 358 | 146.2 | 142.1 | 236.5 | 350.1 | 454.8 |
| P/E ratio | -16.7 x | -6.65 x | -10.3 x | -3.79 x | -2.56 x | -3.55 x | -4.51 x | -21 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 24.6 x | 15.3 x | - | - | - | - | 27.6 x | 3.88 x |
| EV / Revenue | 22.6 x | 10 x | - | - | - | - | 21.2 x | 3.88 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | -4.52 x | -7.29 x | -1.85 x | -1.86 x | -1.71 x | -3.41 x | -12.4 x |
| FCF Yield | - | -22.1% | -13.7% | -54.1% | -53.8% | -58.3% | -29.3% | -8.08% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 17,247 | 17,846 | 24,308 | 24,543 | 34,169 | 42,188 | - | - |
| Reference price 2 | 23.00 | 10.91 | 24.97 | 12.73 | 8.530 | 10.78 | 10.78 | 10.78 |
| Announcement Date | 19-07-15 | 20-06-29 | 21-07-13 | 22-07-07 | 23-07-07 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 16.13 | 12.69 | - | - | - | - | 16.49 | 117.3 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -29.82 | -40.53 | -57.92 | -96.61 | -110.9 | -126.1 | -115.2 | -34.43 |
| Operating Margin | -184.91% | -319.41% | - | - | - | - | -698.41% | -29.36% |
| Earnings before Tax (EBT) 1 | -20.69 | -29.24 | -46.24 | -82.34 | -92.91 | -113.6 | -105.7 | -25.34 |
| Net income 1 | -20.82 | -29.12 | -46.24 | -82.34 | -92.91 | -114 | -109.8 | -26.74 |
| Net margin | -129.08% | -229.44% | - | - | - | - | -665.69% | -22.8% |
| EPS 2 | -1.380 | -1.640 | -2.420 | -3.360 | -3.330 | -3.038 | -2.388 | -0.5125 |
| Free Cash Flow 1 | - | -28.06 | -49.12 | -79.06 | -76.46 | -138 | -102.6 | -36.74 |
| FCF margin | - | -221.14% | - | - | - | - | -621.89% | -31.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 19-07-15 | 20-06-29 | 21-07-13 | 22-07-07 | 23-07-07 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: April | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | 1.206 | 1.809 | 7.267 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -23.6 | -26.68 | -26.81 | -26.32 | -25.88 | -26.94 | -31.73 | -29.09 | -29.75 | -33.15 | -34.1 | -34.07 | -33.96 | -34.48 | -28.01 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | -2,816.17% | -1,906.1% | -385.46% |
| Earnings before Tax (EBT) 1 | -19.65 | -22.47 | -24.11 | -23.04 | -22.26 | -21.3 | -26.3 | -25.32 | -27.65 | -29.03 | -31.65 | -31.31 | -31.28 | -31.87 | -25.49 |
| Net income 1 | -19.65 | -22.47 | -24.11 | -23.04 | -22.26 | -21.3 | -26.3 | -25.32 | -27.65 | -29.03 | -32.06 | -31.38 | -31.36 | -31.78 | -27.56 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | -2,600.14% | -1,757.2% | -379.23% |
| EPS 2 | -0.8000 | -0.9200 | -0.9800 | -0.9400 | -0.9000 | -0.7500 | -0.7700 | -0.7400 | -0.8000 | -0.8400 | -0.7217 | -0.6733 | -0.6700 | -0.6733 | -0.5733 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-12-09 | 22-03-10 | 22-07-07 | 22-09-08 | 22-12-08 | 23-03-09 | 23-07-07 | 23-09-07 | 23-12-07 | 24-03-11 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 32 | 67.7 | 249 | 166 | 149 | 218 | 105 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -28.1 | -49.1 | -79.1 | -76.5 | -138 | -103 | -36.7 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.08 | 0.22 | 0.08 | 0.93 | 1.2 | 0.23 | 0.8 | 0.83 |
| Capex / Sales | 6.7% | 1.73% | - | - | - | - | 4.83% | 0.71% |
| Announcement Date | 19-07-15 | 20-06-29 | 21-07-13 | 22-07-07 | 23-07-07 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.78
USD
Average target price
30.6
USD
Spread / Average Target
+183.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.00% | 455M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- KALV Stock
- Financials KalVista Pharmaceuticals, Inc.
